<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>exhibit1.htm
<DESCRIPTION>TKT STOCK REPURCHASE AMENDMENT AGREEMENT
<TEXT>

<HTML>
<HEAD>
<title>Exhibit 99.1</title>
</HEAD>
<body bgcolor=white>

<DIV align=left>
<HR align=left SIZE=2 width="100%">
</DIV>
<DIV align=left>
<HR align=left SIZE=2 width="100%">
</DIV>

<h5>Exhibit 99.1</h5>

<B><FONT SIZE=5><P ALIGN="CENTER">STOCK REPURCHASE AND AMENDMENT AGREEMENT </P>
</FONT><P ALIGN="JUSTIFY">&nbsp This Amendment Agreement</B> (the
&quot;<I>Amendment</I>&quot;) is made and entered into as of January 17, 2003
(the &quot;Amendment Effective Date&quot;), by and between Transkaryotic
Therapies, Inc., a Delaware corporation (&quot;<I>TKT</I>&quot;), and Cell
Genesys, Inc., a Delaware corporation (&quot;<I>CELL GENESYS</I>&quot;).  TKT
and CELL GENESYS may be referred to herein as a &quot;Party&quot; or,
collectively, as &quot;Parties&quot;.</P>
<B><P ALIGN="JUSTIFY">&nbsp A.</B>&#9;CELL GENESYS and TKT are party to that certain
License Agreement dated June 7, 2002 pursuant to which CELL GENESYS licensed to
TKT rights to certain technology (the &quot;<I>License Agreement</I>&quot;) and
that certain Stock Purchase Agreement dated June 7, 2002 (the &quot;<I>Stock
Purchase Agreement</I>&quot;).</P>
<B><P ALIGN="JUSTIFY">&nbsp B.&#9;</B>In partial consideration for the license granted
to TKT by CELL GENESYS, TKT issued to CELL GENESYS  Three-Hundred Sixty Six
Thousand Nine Hundred Twenty Eight (366,928) shares of TKT Common Stock, subject
to adjustment in accordance with the terms of the Stock Purchase Agreement (the
&quot;<I>Upfront Shares</I>&quot;). </P>
<B><P ALIGN="JUSTIFY">&nbsp C.</B>&#9;The number of Upfront Shares was calculated to
give effect to the agreement of the parties that the value of the Upfront Shares
would equal $15,000,000.  </P>
<B><P ALIGN="JUSTIFY">&nbsp D.</B>&#9;Pursuant to the Stock Purchase Agreement, TKT
agreed to use commercially reasonable efforts to register the Upfront Shares
under the Securities Act of 1933, as amended, but such shares are not yet
registered.  In addition, the number of Upfront Shares is subject to adjustment
at the time of registration based on the average closing price of TKT common
stock for a specific time period, as provided in the  Stock Purchase
Agreement.</P>
<B><P ALIGN="JUSTIFY">&nbsp E.</B>&#9;The Parties desire to effect a rescission of the
obligation by TKT to issue the Upfront Shares, and replace such obligation with
a cash payment by TKT to CELL GENESYS.  In connection therewith, the Parties
desire that (i) CELL GENESYS sell to TKT and TKT repurchase from CELL GENESYS
the Upfront Shares, and (ii) the terms of the License Agreement and of the Stock
Purchase Agreement be amended, as provided herein, to eliminate the requirement
to register the Upfront Shares and adjust the number of Upfront Shares, all for
aggregate consideration of $15,000,000.</P>
<B><P ALIGN="CENTER">AGREEMENT</P>
</B><P ALIGN="JUSTIFY">&nbsp In consideration of the mutual covenants contained in
this Amendment and for other good and valuable consideration, the receipt of
which is hereby acknowledged, CELL GENESYS and TKT hereby agree as follows:</P>
<OL>

<B><P ALIGN="JUSTIFY">SECTION 1.  Amendment of the Stock Purchase Agreement</P>
</B><P ALIGN="JUSTIFY">TKT shall have no further obligation under the Stock
Purchase Agreement to (i) issue any shares of its common stock pursuant to the
adjustment provisions of Section 1.2 or (ii) register the Upfront Shares.  In
connection with the repurchase of the Upfront Shares, the  Parties hereby agree
that the terms of the Stock Purchase Agreement are hereby amended as provided
below, to eliminate the requirement that the Upfront Shares be adjusted under
certain circumstances and to eliminate TKT's obligation to register the Upfront
Shares  To the extent that the Stock Purchase Agreement is explicitly amended by
this Amendment, the terms of the Amendment will control where the terms of the
Stock Purchase Agreement are contrary to or conflict with the following
provisions.  Where the Stock Purchase Agreement is not explicitly amended, the
terms of the Stock Purchase Agreement will remain in force.  </P>
<P ALIGN="JUSTIFY">Capitalized terms used in this Amendment that are not
otherwise defined herein shall have the same meanings given them in the Stock
Purchase Agreement.  </P>
<OL>

<B><P ALIGN="JUSTIFY">1.1  Amendment of Section 1.1(a) of the Stock Purchase
Agreement.  </B>The words &quot;subject to adjustment pursuant to Section
1.2&quot; are hereby deleted from Section 1.1(a) of the Stock Purchase
Agreement.</P>
<B><P ALIGN="JUSTIFY">1.2  Deletion of Section 1.2.  </B>Section 1.2 of the Stock
Purchase Agreement is hereby deleted in its entirety. </P>
<B><P ALIGN="JUSTIFY">1.3  Amendment of Section 8.1(a) of the Stock Purchase
Agreement.  </B>Section 8.1(a) of the Stock Purchase Agreement is hereby deleted
in its entirety and replaced with the following:</P>

<P ALIGN="JUSTIFY"><A NAME="_Toc11244059">&quot;`<I>Registrable Shares</I>'
shall mean all Shares issued pursuant to this Agreement (which, for greater
certainty, shall include the First Milestone Shares and the Second Milestone
Shares, when issued) and any other shares of Common Stock issued or issuable in
respect to the Shares (because of stock splits, stock dividends,
reclassifications, recapitalizations, adjustments pursuant to this Agreement or
similar events), <I>provided, however</I>, that `Registrable Shares' shall not
include the Up Front Shares;</A>&quot;</P>
<B><P ALIGN="JUSTIFY">1.4  CELL GENESYS' Authority to Sell the Upfront
Shares.</P>
</B><P ALIGN="JUSTIFY">&#9;(a) &#9;CELL GENESYS has good and marketable title to
the Upfront Shares which are to be transferred to TKT by CELL GENESYS pursuant
hereto, free and clear of any and all covenants, conditions, restrictions,
voting trust arrangements, liens, charges, encumbrances, options and adverse
claims or rights whatsoever, other than those existing under the terms of the
Stock Purchase Agreement.  </P>
<P ALIGN="JUSTIFY">&#9;(b) &#9;

CELL GENESYS has the full right, power and authority to enter
into this Agreement and to transfer, convey and sell to TKT at the Closing the
Upfront Shares to be sold  hereunder and, upon consummation of the purchase
contemplated hereby, TKT will acquire from CELL GENESYS good and marketable
title to such Upfront Shares, free and clear of all covenants, conditions,
restrictions, voting trust arrangements, liens, charges, encumbrances, options
and adverse claims or rights whatsoever, other than those existing under the
terms of the Stock Purchase Agreement.</P></OL>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">SECTION 2.  Amendment of the License Agreement</P>
</B><P ALIGN="JUSTIFY">In connection with the repurchase of the Upfront Shares
and the amendments to the Stock Purchase Agreement contemplated by Section 1
hereof, the Parties hereby agree that TKT shall have no further obligation to
issue any shares of its common stock as the initial license fee under Section
4.1 of the License Agreement or make any other payments as the initial license
fee under Section 4.1 of the License Agreement and that the terms of the License
Agreement are hereby amended as provided below, to delete the references therein
to the Upfront Shares, the requirement that the Upfront Shares be adjusted under
certain circumstances and the obligation of TKT to register the Upfront Shares.
To the extent that the License Agreement is explicitly amended by this
Amendment, the terms of the Amendment will control where the terms of the
License Agreement are contrary to or conflict with the following provisions.
Where the License Agreement is not explicitly amended, the terms of the License
Agreement will remain in force.</P>
<OL>

<B><P ALIGN="JUSTIFY">2.1  Amendment of Exhibit A to the License Agreement.
</B>Exhibit A to the License Agreement is hereby amended to give affect to the
amendments to the Stock Purchase Agreement described in Section 1
hereof.</P></OL>

<B><P ALIGN="JUSTIFY">SECTION 3.&nbsp  Repurchase of Upfront Shares</P>
<OL>

<P ALIGN="JUSTIFY">3.1  Purchase and Sale.</B>  TKT will repurchase from CELL
GENESYS, and CELL GENESYS will sell to TKT, all of the Upfront Shares, comprised
of Three-Hundred Sixty Six Thousand Nine Hundred Twenty Eight (366,928) shares
of TKT Common Stock, par value $0.01 per share, and CELL GENESYS will agree to
the amendment of the Stock Purchase Agreement and the License Agreement, as set
forth herein, for aggregate consideration of Fifteen Million Dollars
($15,000,000) paid by TKT to CELL GENESYS<B><I> </B></I>(the &quot;<I>Repurchase
Price&quot;)</I>.</P>
<B><P ALIGN="JUSTIFY">3.2  Closing.</B>  The closing of the repurchase and sale
of the Upfront Shares pursuant to this Amendment shall be held at the offices of
Hale and Dorr LLP, 60 State Street, Boston, Massachusetts, 02109, on the
Amendment Effective Date (such date is hereinafter referred to as the
&quot;Repurchase Closing&quot;).</P>
<B><P ALIGN="JUSTIFY">3.3  Delivery.</B>  At the Repurchase Closing, subject to
the terms and conditions hereof, CELL GENESYS will deliver the stock certificate
or certificates representing the Upfront Shares, against payment of the
Repurchase Price therefore by wire transfer of immediately available funds to
CELL GENESYS.</P></OL>

<B><P ALIGN="JUSTIFY">SECTION 4.  Release and Waiver</P>
<OL>

<P ALIGN="JUSTIFY">4.1  Release by CELL GENESYS.</B>  Effective upon completion
of the Repurchase Closing, CELL GENESYS, on behalf of itself and its affiliates,
assigns, agents and shareholders, releases and forever discharges TKT and its
officers, directors, shareholders, agents, affiliates, attorneys and employees
from any claims, causes of actions, damages, losses, or liabilities
(collectively, the &quot;<I>Claims</I>&quot;) of any kind or nature, known or
unknown, direct, indirect, or derivative, accrued or unaccrued, that CELL
GENESYS or any of its affiliates, assigns, agents, or shareholders had, have, or
hereafter may have concerning, arising from or in any way related to the Upfront
Shares, including without limitation, any Claims concerning, arising from or in
any way related to Sections 1.1(a), 1.2 and 8.2 of the Stock Purchase
Agreement.</P>
<B><P ALIGN="JUSTIFY">4.2  Waiver and Release by TKT.</B>  Effective upon the
Repurchase Closing, TKT waives all restrictions on Transfer of the Upfront
Shares imposed by the Stock Purchase Agreement.  Effective upon completion of
the Repurchase Closing, TKT, on behalf of itself and its affiliates, assigns,
agents and shareholders, releases and forever discharges CELL GENESYS and its
officers, directors, shareholders, agents, affiliates, attorneys and employees
from any Claims of any kind or nature, known or unknown, direct, indirect, or
derivative, accrued or unaccrued, that TKT or any of its affiliates, assigns,
agents, or shareholders had, have, or hereafter may have concerning, arising
from or in any way related to the Upfront Shares, including without limitation,
any Claims concerning, arising from or in any way related to Sections 4.2 and
4.3 of the Stock Purchase Agreement, to the extent related to the Upfront
Shares.</P></OL>

<B><P ALIGN="JUSTIFY">SECTION 5.  <A NAME="_Toc11244085">Miscellaneous.</A></P></B>
<OL>

<B><P ALIGN="JUSTIFY">5.1  <A NAME="_Toc11244086">Waivers
and Amendments.</B> Neither this Amendment nor any provision hereof may
be changed, waived, discharged, terminated, modified or amended except upon the
written consent of the Parties.</A></P>
<B><P ALIGN="JUSTIFY">5.2  <A NAME="_Toc11244087">
Headings.</B> The headings of the various sections of
this Amendment have been inserted for convenience of reference only and shall
not be deemed to be part of this Amendment.</A></P>
<B><P ALIGN="JUSTIFY">5.3  <A NAME="_Toc11244088">
Severability.</B> If any provision hereof should be held
invalid, illegal or unenforceable in any respect, then, to the fullest extent
permitted by law, (a) all other provisions hereof shall remain in full force and
effect and shall be liberally construed in order to carry out the intentions of
the Parties as nearly as may be possible and (b) the parties shall use their
best efforts to replace the invalid, illegal or unenforceable provision(s) with
valid, legal and enforceable provision(s) which, insofar as practical, implement
the purposes of such provision(s) in this Amendment.</A></P>
<B><P ALIGN="JUSTIFY">5.4  <A NAME="_Toc11244089">Governing
Law</B>.  This Amendment shall be governed by and construed in accordance
with the laws of the State of Delaware as applied to contracts entered into and
performed entirely in the State of Delaware by Delaware residents, without
regard to conflicts of law principles.</A></P>
<B><P ALIGN="JUSTIFY">5.5  <A NAME="_Toc11244090">
Counterparts.</B> This Amendment may be executed in two
or more counterparts, each of which shall constitute an original, but all of
which, when taken together, shall constitute but one instrument, and shall
become effective when one or more counterparts have been signed by each party
hereto and delivered to the other parties.</A></P></OL>
</OL>

<B><P ALIGN="JUSTIFY"></P>
</B><P ALIGN="CENTER">[Signature page follows.]</P>
<B><P ALIGN="CENTER">In Witness Whereof</B>, the Parties hereto have executed
this Amendment in duplicate originals by their authorized officers as of the
Amendment Effective Date.</P>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="50%" VALIGN="TOP">
<B><P ALIGN="JUSTIFY">Transkaryotic Therapies, Inc.</P>
</B><P ALIGN="JUSTIFY">&#9;&#9;</P>
<P ALIGN="JUSTIFY">By: /s/ Richard F. Selden <U><BR>
</P>
</U><P ALIGN="JUSTIFY">Name: Richard F. Selden </P>
<P ALIGN="JUSTIFY">Title: President</TD>
<TD WIDTH="50%" VALIGN="TOP">
<B><P ALIGN="JUSTIFY">Cell Genesys, Inc.</P>
</B><P ALIGN="JUSTIFY">&#9;&#9;</P>
<P ALIGN="JUSTIFY">By: /s/ Robert H. Tidwell <U><BR>
</P>
</U><P ALIGN="JUSTIFY">Name: Robert H. Tidwell</P>
<P>Title: Senior Vice President</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>

<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
</B><P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>


<br>
<br>
<br>
<HR WIDTH="85%">
<br>
<br>
<br>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
